Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Viloxazine has a long history of clinical use in Europe as an antidepressant, and has
recently been repurposed into an extended-release form for the treatment of attention …

Background and objective Attention-deficit/hyperactivity disorder is a neurodevelopmental
disorder that typically begins in childhood and often persists into adulthood. Recent phase III …

Stimulants (methylphenidate or amphetamines) are the recommended first-line option for the
pharmacological treatment of individuals with attention deficit hyperactivity disorder (ADHD) …

Background Recently, the United States Food and Drug Administration (USFDA) approved
viloxazine extended-release (ER) to manage attention-deficit hyperactivity disorder (ADHD) …

Viloxazine is a recently approved, non-stimulant medication functions by inhibiting the
uptake of norepinephrine which has been seen to be decreased in patients with ADHD …

Purpose The ADHD Rating Scale (ADHD-RS) assesses 18 symptoms of inattention and
hyperactivity/impulsivity and has been used in many clinical trials to evaluate the treatment …

Aim The aim of this study was to evaluate the effect of viloxazine extended-release capsules
(viloxazine ER; Qelbree™) on executive function deficits (EFDs) in pediatric subjects (6–17 …

Viloxazine extended‐release capsules (viloxazine ER; Qelbree) is a novel nonstimulant,
recently approved by the US Food and Drug Administration for the treatment of ADHD in …

Introduction Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral
disorder with symptoms that may persist in up to 90% of adults diagnosed during childhood …